GB2622629A - Method - Google Patents
Method Download PDFInfo
- Publication number
- GB2622629A GB2622629A GB2213924.0A GB202213924A GB2622629A GB 2622629 A GB2622629 A GB 2622629A GB 202213924 A GB202213924 A GB 202213924A GB 2622629 A GB2622629 A GB 2622629A
- Authority
- GB
- United Kingdom
- Prior art keywords
- neurons
- aav
- aav viral
- population
- viral particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 76
- 210000002569 neuron Anatomy 0.000 claims abstract description 136
- 210000000234 capsid Anatomy 0.000 claims abstract description 112
- 210000002220 organoid Anatomy 0.000 claims abstract description 87
- 239000002245 particle Substances 0.000 claims abstract description 79
- 230000003612 virological effect Effects 0.000 claims abstract description 74
- 210000005056 cell body Anatomy 0.000 claims abstract description 40
- 238000012216 screening Methods 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
- 230000002232 neuromuscular Effects 0.000 claims abstract description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 238000001415 gene therapy Methods 0.000 claims abstract description 17
- 210000002304 esc Anatomy 0.000 claims abstract description 13
- 210000000663 muscle cell Anatomy 0.000 claims abstract description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 6
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 6
- 230000035772 mutation Effects 0.000 claims abstract description 4
- 241000282414 Homo sapiens Species 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 8
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 59
- 210000002161 motor neuron Anatomy 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 15
- 210000003050 axon Anatomy 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 14
- 210000003205 muscle Anatomy 0.000 description 14
- 241000702421 Dependoparvovirus Species 0.000 description 13
- 239000013603 viral vector Substances 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 238000010255 intramuscular injection Methods 0.000 description 10
- 239000007927 intramuscular injection Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 210000000278 spinal cord Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 210000003061 neural cell Anatomy 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 208000012902 Nervous system disease Diseases 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000003306 harvesting Methods 0.000 description 7
- 230000001095 motoneuron effect Effects 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 210000001787 dendrite Anatomy 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000010415 tropism Effects 0.000 description 6
- 239000013607 AAV vector Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 5
- 108010076089 accutase Proteins 0.000 description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000000653 nervous system Anatomy 0.000 description 5
- 210000000063 presynaptic terminal Anatomy 0.000 description 5
- 230000007441 retrograde transport Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 208000008238 Muscle Spasticity Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 210000001153 interneuron Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000001176 projection neuron Anatomy 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 239000011435 rock Substances 0.000 description 4
- 210000001044 sensory neuron Anatomy 0.000 description 4
- 208000018198 spasticity Diseases 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 3
- 102000014461 Ataxins Human genes 0.000 description 3
- 108010078286 Ataxins Proteins 0.000 description 3
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 3
- 206010008025 Cerebellar ataxia Diseases 0.000 description 3
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 208000027747 Kennedy disease Diseases 0.000 description 3
- 201000004767 Lethal congenital contracture syndrome Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 3
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000005064 dopaminergic neuron Anatomy 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 201000010901 lateral sclerosis Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000005264 motor neuron disease Diseases 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000002708 random mutagenesis Methods 0.000 description 3
- 238000007390 skin biopsy Methods 0.000 description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000914334 Sahlbergella singularis Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 206010008129 cerebral palsy Diseases 0.000 description 2
- 210000004720 cerebrum Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 238000001531 micro-dissection Methods 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000007658 neurological function Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 101150066583 rep gene Proteins 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VFSUUTYAEQOIMW-YHBQERECSA-N 3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-[3-(pyridin-4-yl)benzyl]-1-benzothiophene-2-carboxamide Chemical compound C1C[C@@H](NC)CC[C@@H]1N(C(=O)C1=C(C2=CC=CC=C2S1)Cl)CC1=CC=CC(C=2C=CN=CC=2)=C1 VFSUUTYAEQOIMW-YHBQERECSA-N 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000293679 Boraria media Species 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000003766 afferent neuron Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000000401 corticothalamic effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011977 dual antiplatelet therapy Methods 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- -1 e.g. Substances 0.000 description 1
- 210000000268 efferent neuron Anatomy 0.000 description 1
- 238000001537 electron coincidence spectroscopy Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000005156 neurotropism Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C12N15/8616—Special methods for targeting systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0661—Smooth muscle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2500/00—Analytical methods involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2541/00—Reactions characterised by directed evolution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A method of screening for capsid-encoding nucleotide sequences of AAV viral particles capable of infecting population-specific neurons. The method comprises (i) obtaining a neuromuscular organoid comprising neurons and muscle cells, wherein the neurons are disposed in the organoid such that the cell body and distal portion are distally separated from each other, (ii) contacting and infecting the distal portion of the neurons with AAV viral particles, (iii) recovering AAV particles from the cell body, (iv) determining the capsid encoding nucleotide sequences of the AAV viral particles recovered. The neuromuscular organoid can be from iPSCs or ESCs. A further aspect is a method of directed evolution selecting for AAV particles capable of selectively infecting population-specific neurons comprising steps (i) to (ii) and optionally comprising step (v) using the output of step (iv) to generate an AAV viral particle library and repeating the method. A further aspect are AAV viral particles capable of infecting population specific neurons. The AAV viral particle can comprise a nucleotide-encoded payload. The payload can encode a therapeutic peptide. The payload can be a gene therapy payload. A further aspect is the use of the AAV viral particles in treating a disease caused by a genetic mutation.
Description
METHOD
Field of the Invention
The present invention relates to a method of screening AAV viral particle libraries in organoids, specifically screening for capsids that a capable of specifically infecting a population of cells, such a neurons, in preference to other cell types or populations. The invention also relates to a method of directed evolution by repeating the screening method, to the AAV viral particles obtained or evolved using the method and to a method using the AAV viral particles to infect a specific population of cells.
Background to the Invention
Adeno-associated viruses (AAV) are important vectors for gene therapies. Numerous naturally occurring AAV serotypes have been identified, each with differences in the coding sequence for the viral capsid. These differences in the capsid result in altered cellular tropism, that is, different AAV serotypes will differentially infect different cell types (Castle et al., 2016).
Naturally occurring AAV serotypes have been used in both clinical trials and in approved gene therapies. However, the prevalence of antibodies against natural AAVs in the human population, as well as the inability of natural serotypes to efficiently target certain cell types, means that synthetic (non-wildtype) capsids have become increasingly popular for genetic medicines (Kuzmin et al., 2021).
Synthetic AAV capsids have amino acids sequences that are broadly similar to naturally occurring capsids but are built in the lab via random mutagenesis, DNA shuffling or other synthetic biology techniques. Synthetic capsids can be rationally designed, for example by the insertion of peptide sequences that have potentially useful properties. Alternatively, a large, diverse library of random capsids can be generated (Korbelin et al., 2017). Typical libraries can contain up to 10' different variants and a directed evolution approach is used to identify those variants that have desirable properties from this large pool. Desirable qualities include infection of a particular cell type of interest (Bartel et al., 2012), such as neurons, as well as detargeting from other cell types or organs that it is not desirable to target, such as the liver.
Directed evolution of AAV capsids from a library can be done in vivo or in vitro for example, by injecting the library into an animal then harvesting the target tissue or cell type (Figure 1A). If required, this first round of evolution can be supplemented with further rounds, whereby the harvested capsid DNA is further mutated or modified, and the screening process repeated (Grim and Bueng, 2017).
As is generally the case with directed evolution approaches "you get what you screen for". That is to say, the closer that your screening environment replicates the final targeted system, the more likely it is that you will find candidates that possess the desired properties (Schmidt-Dannert and Arnold. 1999). For gene therapy approaches, it is therefore critical that the screening of AAV capsid libraries occurs in a system that resembles the final human patient as closely as possible.
Directed evolution of AAV capsids often occurs in experimental animals, such as mice or non-human primates (NHP). Mice are favoured due to their widespread availability in experimental research and ease of genetic manipulation, whereas NHP are evolutionarily closer to humans. In both cases, the capsid libraries are injected into experimental animals, the tissue or cell type of interest harvested after an incubation period, and the AAV particles recovered are then sequenced to identify useful capsids. As expected, capsid evolution that occurs in mice results in capsids that are effective in mice but not in NHP (Ligoure et al., 2019), with capsid properties also being tied to the precise strain of mouse used (Mathieson et al., 2020). Consequently, the most effective capsid evolution strategies, at present, use a combination of animal screening and validation on human cells (see Tabebordbar et al., 2021).
Organoids can be defined as a 3D structure, grown from stem and progenitor cells (induced pluripotent stem cells, IPSCs; embryonic stem cells, ESCs) and consisting of organ-specific cell types. These cell types self-organise through cell sorting and spatially restricted lineage to form a representation of specific (human) tissue "in a dish" (Bredenoord et al., 2017). Numerous different types of organoids have been developed for a variety of human tissues, including: parts of the gastric system, small intestine, colon, liver, pancreas, trachea, pulmonary alveolus, thyroid, oesophagus, prostate, fallopian tube, kidney, and various parts of the nervous system such as: the retina, cerebellum, cerebrum, olfactory bulb, hippocampus, hypothalamus, choroid plexus, spinal cord and neuromuscular system (see Rossi et al., 2018).
A number of studies have used organoids to test whether previously identified capsids (either synthetic or wildtype capsids) would be efficacious in human tissues. For example, Achberger et al. (2021) recently used retinal organoids to test the tropism of seven different AAV vectors (both wildtype and synthetic) to assess which had the best tropism, efficacy and kinetics in human tissue. Similarly, GaritaHernandez et al. (2020) used retinal organoids to test the efficacy of several AAV serotypes in human retinas, and McClements et al. (2022) used retinal organoids to evaluate the effectiveness of both AAV capsids and promoters in gene expression in photoreceptors. Depla et al. (2020) used human cerebral organoids to test the efficacy of two AAV serotypes, AAV5 and AAV9, in a human context. They found that AAVS provided superior transduction.
Outside of the nervous system, human organoids have been used to test the ability of different AAV serotypes to infect the lung (Meyer-Berg et al., 2020) and to screen six different synthetic capsids for their ability to infect cell types in kidney organoids (Ikeda et al., 2018).
The above studies represent the use of human organoids in the testing of AAV capsids which have previously been identified by other means. Importantly, they demonstrate the belief that human tissues in vitro will provide a superior environment for testing of human therapeutics than animal models. However, there are no studies, or descriptions, of using human tissues or organoids as a vehicle to search for and identify novel AAV capsids.
The present disclosure relates to a method of screening AAV capsids using organoids to select for a capsids that selectively infect a particular cell type and to a method of directed evolution using the same organoid. The method presents the first step in identifying novel vectors for gene therapy.
Summary of the Invention
According to a first aspect there is provided a method of screening for capsid-encoding nucleotide sequences of AAV viral particles capable of infecting population-specific neurons, the method comprising: (I) obtaining or having obtained a neuromuscular organoid comprising neurons and muscle cells, wherein the neurons, having a cell body and a distal portion located away from the cell body, are disposed in the organoid such that the cell body and the distal portion are distally separated from each other; (ii) contacting the distal portion of the neurons with a population of AAV viral particles such that they can infect the neuron at the distal portion; (iii) recovering AAV viral particles that have infected the distal portion of the neurons from the cell body; and (iv) determining the capsid encoding nucleotide sequences of the AAV viral particles recovered from the cell body.
In a second aspect there is provided a method of directed evolution to select for AAV viral particles capable of selectively infecting population-specific neurons comprising the steps: (i) obtaining or having obtained a neuromuscular organoid comprising neurons and muscle cells, wherein the neurons, having a cell body and a distal portion located away from the cell body, are disposed in the organoid such that the cell body and the distal portion are distally separated from each other; (ii) contacting the distal portion of the neurons with a population of AAV viral particles such that they can infect the neuron at the distal portion; (iii) recovering AAV viral particles that have infected the distal portion of the neurons from the cell body; (iv) determining the capsid encoding nucleotide sequences of the AAV viral particles recovered from the cell body, and (v) optionally using the output of step (iv) to generate a new AAV viral particle library and repeating the method.
In one embodiment the neuromuscular organoid is derived from iPSCs or ESCs.
In one embodiment the population-specific neurons are selected from the list consisting: mammalian, human, human sub-population and human disease-specific.
In one embodiment the human disease-specific population-specific neurons are selected from the list: M ND, DM, ALS, HD, epilepsy, neuropathy, PD, SCA, HSP, PLS, SMA, SBMA and LCCS neurons.
In a third aspect there is provided AAV viral particles capable of infecting population-specific neurons identified or selectively evolved according to the method disclosed herein.
In a fourth aspect there is provided the use of the AAV viral particles according to the present disclosure to selectively infect population-specific neurons.
In one embodiment the AAV viral particle comprises a nucleotide-encoded payload.
In one embodiment the nucleotide-encoded payload encodes a therapeutic peptide. In one embodiment the nucleotide-encoded payload is a gene therapy payload.
In a further aspect there is provided the use of the AAV viral particles disclosed hereing in the treatment of a disease caused by a genetic mutation.
The invention provides an AAV capsid identified by a screening method of the invention.
Advantageously, the AAV capsids identified by the screening methods described herein may be used to develop gene therapies for treating various conditions or disorders. Accordingly, the AAV capsids may be employed in a method of ameliorating or treating a neuromuscular or neuromotor condition or disorder in a subject, comprising administering to the subject a therapeutically active amount of an AAV expression vector or viral particle of the invention.
Brief Description of the Drawings
For a better understanding of the invention and to show how the same may be carried into effect, there will now be described by way of example only, specific embodiments, methods and processes according to the present invention with reference to the accompanying drawings in which: Figure 1A shows a prior art method of directed evolution of AAV capsids in which an AAV genome capsid library is generated that contain a wide range of capsid variants and packaged into an AAV vector capsid library. The library is injected into an experimental animal (19) and then capsids/AAVs are harvested from target tissues (20) and sequenced.
Figure 1B shows a flowchart of the method of identification of AAV capsid variants from an organoid in which 1 -generation of tissue specific organoid, 2-infection of organoid with AAV capsid library, 3 -harvesting of capsid DNA or RNA from organoid cell type of interest, 5 -sequencing and analysis of enriched variants and 4-production of new library.
Figure 2 shows an example use of neuromuscular organoids to screen for motor neuron targeted AAV capsids.
2A shows a spinal-neuromuscular organoid with a spatially separated spinal cord compartment (9) containing interneurons (6) and motor neurons (7) and an innervated muscle compartment (10) containing motor neuron axons and synaptic terminals (8).
2B shows microinjection (11) of the AAV capsid library (12) into the muscle compartment, some members of the library infect the motor neuron synaptic terminal and are retrogradely transported within the motor neuron axon (13) to the motor neuron cell body (14) within the spinal cord compartment and release of the capsid DNA occurs.
2C shows microdissection and harvesting of the motor neurons (7) and dissociation of the cell bodies (16) from the rest of the tissue.
2D cells are lysed (17) to release capsid DNA and this DNA (18) is then sequenced to identify capsids that have infected motor neurons. These capsids can then be further validated and subjected to additional rounds of evolution
Detailed Description
As employed herein screening refers to a method of selectively identifying members of a population for desirable properties. Herein, the population is an AAV library, or AAV viral particle library and the desirable property is the ability to selectively infect population-specific cells, such as population-specific neurons.
As employed herein capsid-encoding nucleotide sequences refers to nucleotide sequence encoding the capsid proteins. Typically, the nucleotide sequence is a DNA sequence, although RNA, modified nucleotide and synthetic nucleotides are also envisioned.
As employed herein AAV viral particles refers to adeno-associated virus viral particles comprising a single stranded DNA genome packaged within a viral envelope that is capable of infecting a cell, e.g. a mammalian cell. In particular, the AAV viral particles employed herein include the nucleotide sequence for the capsid that is packaging the nucleotide sequence. In some embodiments the viral particles may be devoid of replication-encoding nucleotides, that is, they are replication deficient.
AAVs are small viruses belonging to the genus dependoparvovirus containing a single strand of DNA, up to -4.9 Kb. The AAV genome contains three capsids proteins VP1, VP2 and VP3, all of which are translated from one mRNA via alternate splicing. In the wild, multiple serotypes of AAV have been identified each with unique sequences of capsid gene, and hence distinct tropisms, although wild serotypes tend to be able to infect multiple tissue and cell types. These serotypes are denoted by numbers: AAV1, AAV2, etc. It has been shown that modification of capsid sequences via DNA recombination methods can generate non native sequences with tailored properties and tropism directed towards (or against) particular cells or tissues, and that evade the immune system (Vandenberghe et al., 2009).
Modifications to capsids can be achieved in several ways, such as random mutagenesis of existing capsid DNA sequences, by capsid shuffling (i.e. taking DNA sequences from multiple capsids and randomly shuffling parts of the sequence to make a new capsid; Buning et al., 2015), or by insertion of short peptide sequences into the exposed loop regions of the capsid. These methods can generate a large number of highly diverse capsids with potentially valuable properties. When packaged into functional virions, they can be screened in animal tissues or in cell cultures to select those capsids that are targeted towards particular tissues or cells. These capsid sequences can then be generated de novo and combined with genes with therapeutic potential in a gene therapy.
As employed herein "capable of infecting population-specific neurons" refers to the ability to selectively infect a particular cell type such as neurons rather than muscle tissue.
However, population-specific may further refer to selectively infecting, for example, animal neurons or human neurons, such as human neurons rather than rat neurons.
Further, the method described herein may be used to identify viral particles capable of infecting a sub-population of neurons, for example, disease-state human neurons rather than non-disease-type neurons. Such as Duchenne muscular dystrophy (DM), Amyotrophic lateral sclerosis (ALS), Epilepsy, Huntington disease (HD), neuropathy, Parkinson disease (PD), Spinocerebellar Ataxia (SCA), hereditary spastic paraplegia (HSP), primary lateral sclerosis (PLS), spinal muscular atrophy (SMA), spinal bulbar muscular atrophy (SBMA) and lethal congenital contracture syndrome (LCCS) or other genetic disorders.
Furthermore, population-specific may relate to the ability to selectively infect one part of a neuron, such as the axon or dendrite, rather than the cell body.
As employed herein, the term neuron includes a neuron and a portion or portions thereof (e.g., the neuron cell body, an axon or a dendrite). The term neuron as used herein denotes nervous system cells that include a central cell body (or soma) and two types of extensions or projections: dendrites, by which the majority of neuronal signals are conveyed to the cell body, and axons, by which the majority of neuronal signals are conveyed from the cell body to effector cells, such as target neurons or muscle. Neurons can convey information from tissues and organs into the central nervous system (afferent or sensory neurons) and transmit signals from the central nervous systems to effector cells (efferent or motor neurons). Other neurons, designated interneurons, connect neurons within the central nervous system (the brain and spinal cord). Yet more neurons, designated project (or "projection") neurons, extend their axons from one region of the nervous system to another. The screening methods disclosed herein may be used to screen for capsid-encoding nucleotide sequences of adeno-associated virus ("AAV") particles capable of infecting such neurons.
It will be appreciated that the method disclosed herein may be applicable to cell types other than neurons.
In some embodiments the population-specific neurons are motor neurons. In other embodiments the population-specific neurons are sensory neurons In some embodiment the population-specific neurons are interneurons (or genetically defined subtypes).
In some embodiments the population-specific neurons are projection neurons (or genetically defined subtypes).
In one embodiment the population-specific neurons are human neurons.
In one embodiment the population-specific neurons are disease-state human neurons.
As employed herein disease-state neurons means neurons or neuronal subtypes implicated in the pathophysiology of a particular disease. For example, dopaminergic neurons in Parkinson's disease or motor neurons in amyotrophic lateral sclerosis etc. As employed herein organoid refers to a miniaturised and simplified version of an organ produced in vitro in three dimensions that shows realistic micro-anatomy. They are derived from one or a few cells from a tissue, embryonic stem cells or induced pluripotent stem cells, which can self-organise in three-dimensional culture owing to their self-renewal and differentiation capacities. In the example of neuromuscular organoids, these comprise of both muscle and neurons and may comprise both motor-neurons and spinal cord. Neuromuscular organoids are described, for example, in Martins et al. (2020), Periera et al. (2021), and Andersen et al. (2020). Other types of nervous system organoid are envisioned in the current invention, such as retinal, cerebellum, cerebrum, spinal cord etc. In one embodiment the organoid is derived from iPSCs or ESCs. In one embodiment the organoid is a human organoid.
In one embodiment the organoid is a human disease-state organoid. In one embodiment the organoid is a neuromuscular organoid.
As employed herein, a disease-state organoid is an organoid grown from cells or tissues known to carry a genetic mutation that results in a pathology.
Distally separated as employed herein means that the parts of the neuron are located in physically distanced parts of the organoid such that viral particles can be delivered to a part of the neuron, such the axon or dendrite, in preference to another, such as the cell body. Advantageously, by recovering only viral particles that are found, for example, in the cell body, or spinal cord it is possible to determine which particles can infect neurons.
Distal portion as employed herein refers to parts of the neuron that are distal to the cell body, such as the axon and dendrites, particularly the axon.
Without wishing to be bound by theory, it is thought that some AAV particles may target receptors specifically located at the axon and infect the neuron using these receptors.
As employed herein, "contacting the distal portion of the neurons with a population of viral particles such that they can infect the neuron at the distal portion" refers to any method of exposing the distal portion of the neuron to the viral particles. This can include, but is not limited to injection, microinjection into a particular compartment of the organoid (such as the muscle compartment of a neuromuscular organoid) or inclusion of AAV vectors in the culture media.
As employed herein "recovering viral particles that have infected the distal portion of the neurons from the cell body" refers to any method of selectively recovering only viral particles that have successfully infected the neuron by harvesting the cell body. This can include, but is not limited to, harvesting of a component of the culture, such as microdissection of the spinal cord compartment in a neuromuscular organoid, or harvesting of targeted cell types via somatic inclusion of a fluorophore in the targeted cell type followed by dissociation of the organoid and fluorescent activated cell sorting (FACS). As employed herein "determining the capsid encoding nucleotide sequences of the viral particles recovered from the cell body" refers to sequencing of the viral particle nucleotide sequence of those viral particles recovered from the cell body, typically using high throughput sequence of the type known in the art, such as next generation sequencing (NGS).
Advantageously, the nucleotide sequences of viral particles harvested from the cell body can be compared to those of either the library as a whole or to another source, such as those gathered from muscle cells in the neuromuscular organoid or separate classes of neuron, for example. Comparison of the differences between these sequences enables trends to be identified and further AAV libraries to be rationally designed.
Advantageously, the viral nucleotide sequences can then be analysed and used to generate new libraries that may be used in the screening method described herein to provide in a novel directed evolution method.
In vivo studies have shown that directed evolution of AAV capsids can lead to vectors that have useful properties such as an ability to cross the blood brain barrier and increased neurotropism (Deverman et al., 2016 and EP304431881), or directed towards dopaminergic neurons (Daviddson et al., 2019) or cardiomyocytes (Yang et al., 2009) amongst others (for review see Li and Sumulski, 2020). Examples of directed evolution include the generation of a capsid library, a mixture of AAV vectors encapsidated with random capsid sequences generated via error prone PCR, capsid shuffling, or other methods. These libraries have been applied to cell lines (e.g. Maheshri et al., 2006), undifferentiated stem cells (Asuri et al., 2012) or, most commonly, in experimental animals (for examples Devermann et al., 2016; Li and Sumulski, 2020; Patents US863276482; US20170166926A1; US970198482). The present invention advantageously provides a method of directed evolution utilising organoids.
Population-specific AAV viral particle as employed herein refers to an AAV viral particle that selectively infects a population-specific neuron, such as an AAV viral particle identified or evolved using the method disclosed herein.
As discussed above, AAV capsids have the potential for exquisite levels of cell and species tropism but currently available screening technologies fail to fully harness this selectivity and utilise it for therapeutic benefit.
The present invention overcomes these drawbacks and allows for the screening of AAV capsid libraries in organoids derived from induced pluripotent stem cells ("iPSCs") or embryonic stem cells ("ESCs"). Organoids can be derived in vitro from iPSCs or ESCs (Little et al., 2019). As the genetic makeup of these organoids would be more similar to that of human patients than the same cells found in animal models, it is believed that they provide a much more suitable substrate for screening AAV libraries than experimental animals. In some embodiments, the organoids are neuromuscular and the neurons are motor neurons.
The present invention also comprises a viral evolution approach that uses a combination of organoids derived from induced iPSCs and ESCs, and in vitro screening, to identify AAV capsid-encoding nucleotide sequences that allow for AAV capsids that can more efficiently infect neurons, specifically population-specific neurons. In some embodiments, this approach allows for the identification of MV capsidencoding nucleotide sequences that allow for AAV capsids that can more efficiently infect motor neurons via intramuscular injection.
The invention also comprises a technology platform that identifies novel adeno-associated virus (AAV) capsids based on their ability to target population-specific neurons, by using iPSC/ESC-derived organoids. An example use of this is described herein, where AAV capsid libraries can be screened for their ability to efficiently infect population-specific neuron terminals, but the same system may be used to identify capsids targeted to many neuronal types.
Further, as capsid sequences that efficiently infect neurons may vary from subject to subject, the invention further comprises a process whereby skin samples from individual subjects can be taken, the skin sample transformed into stem cells and then organoids, and these organoids from the patient are used to screen for effective AAV vectors, providing a personalised approach to gene therapy.
In some cases, the iPSCs or ESCs are derived from the subject. In some cases, the iPSCs or ESCs are derived from a skin sample of the subject. In some cases, the iPSCs or ESCs are derived from fibroblasts of the subject. In some cases, the subject is a human subject. The iPSCs and ECSs may also be obtained from an animal, a human subject/patient, or from a cell bank. The screening of AAV capsid libraries using iPSCs from a human subject or patient allows for the identification of capsid sequences that infect neurons or other cells from that subject or patient. Accordingly, the capsid sequences can be generated on an individualised basis using this method.
In some cases, the method is a method a screening for capsid-encoding nucleotide sequences of adenoassociated virus ("AAV") particles capable of infecting neurons in a subject via intramuscular injection.
In one embodiment the organoids are derived from iPSCs. In one embodiment the organoids are derived from ESCs.
In some embodiments the iPSCs used in the screening methods described herein are derived from a human test subject.
In some embodiments the iPSCs are derived from a culture of fibroblasts from skin biopsies. Some methods that allow for culturing of fibroblasts from skin biopsies have been previously described (Vangipuram M, Ting D, Kim 5, Diaz R, Schule B. Skin punch biopsy explant culture for derivation of primary human fibroblasts. J Vis Exp. 2013;(77):e3779. Published 2013 Jul 7. doi:10.3791/3779).
In some embodiments the iPSCs used in the screening methods described herein are derived from a human test subject.
In some embodiments the iPSCs are derived from a culture of fibroblasts from skin biopsies of the subject.
Derivation of human fibroblasts into iPSCs can be achieved using a commercial kit such as the CytoTuneIPS Sendai reprogramming kit from ThermoFisher. Further details may be found at https://www.thermofishercom/order/cataloq/product/A16517#/A16517 and https://assets.thermofisher.com/TFS-Assets/LSG/manuals/cytotune ips 20 sendai reproq kit man.pdf.
Recombinant AAV (rAAV) vectors developed using the methods described herein are especially applicable to the treatment of neuromuscular/neuromotor disorders such as spasticity, amyotrophic lateral sclerosis, dystonia, allowing for the introduction of genetic material into motor neurons via intramuscular injection of viral vectors. However, the screening methods defined herein are agnostic to the disease being treated and may be used to screen for capsid sequences that effectively target many neuronal types, and as such could be effective in gene therapy approaches regardless of the neuron disorders (or "neuronal disorders"). It is believed the invention may also be applied to other neuron disorders which currently have little or no effective therapies, as well as to other types of neuron that underlie neurological disorders.
The effectiveness of an AAV particle to infect population-specific neurons can be determined by counting the number of neurons that express the viral DNA.
For example, multiple motor neurons innervate the same targets, e.g. muscle in the case of motor neurons, and the proportion of these neurons that have been transduced by the AAV viral particle can be counted. The effectiveness of an AAV viral particle to infect neurons or specific parts of neurons can also be determined by DNA sequencing or RT-PCR to look at the "copy number" of the viral DNA that is in the neural cell. This would give an estimate of how many times the same cell was infected with the AAV viral particle.
The application of AAV capsid libraries to a distal portion of a neuron (such as the axon, dendrite, neurite, or axon terminator "synaptic terminal") and harvesting genetic material from another region of the cells (such as the cell body) allows for the identification and determination of AAV capsid sequences that have successfully infected those cells via that specific route.
It is believed that the screening methods described herein may be applied to screen for capsid-encoding nucleotide sequences of AAV viral particles capable of infecting other cell types such as sensory neurons, basal ganglia projection neurons, dopaminergic neurons and muscle tissue. Advantageously, this allows the identification of capsid sequences that infect other cell types and allows the capsid to be design away from those sequences, thereby reducing the likelihood of cross-infectivity.
In some cases, the screening methods described herein comprise a step of providing a plurality of test AAV viral particles that have been additionally screened for capability of infecting muscle cells, for example by direct intramuscular injection. Said additional screening may occur before, after or concurrently with screening of the particles for capability of infecting neurons. Advantageously, comparative data of this type permits selection of capsids that target the desired cell types.
In some cases, the screening method can make use of multiple organoids in a single culture system. For example, organ on a chip or organoid fusion technology (Kakni et al., 2022) can be used to maintain multiple organ systems in one in vitro system. For example, dorsal and ventral forebrain organoids can be fused to produce interacting spheroids (Birey et al., 2017); assembled thalamic and cortical organoids contain reciprocal thalamocortocal and corticothalamic organoids (Xiang et al., 2019) and multiple organ systems such as liver, heart and lungs can be integrated into a single chip to study interaction, and in the present example AAV capsid infectivity, across multiple systems (Skardal et al., 2017). The use of multiple organoids in a single culture system would provide a screening environment closer to full human systems and further increase the ability to identify AAV capsids than can target one organ or cell type over another.
The screening method described herein requires generation of AAV viral particle libraries, or capsid libraries. Methods of generating libraries are known in the art. One such method is described in Nonenmacher et al., 2021.
Diverse capsid libraries can be generated through a process of, for example: i) random mutagenesis of naturally occurring capsids, ii) shuffling of naturally occurring capsids, iii) insertion of targeted or random peptide sequences up to 25 amino acids in length at various regions in VP1, VP2 or VP3 of the AAV capsid or iv) a combination of the above.
To generate the library the randomised capsid sequences are cloned into an AAV backbone containing the AAV2 inverted terminal repeats (ITRs; packaging signals) and the AAV rep gene. These DNA plasmids are transfected in to HEK293 in the presence of additional adenoviral genes to facilitate AAV packaging. AAV virions are harvested from HEK293 cells and/or the culture medium, purified and concentrated following standard methods (e.g. Potter et al., 2014 https://dx.doi.ora/10.1038%2Fmtm.2014.34; McClure et al., 2011 htp://dx.doi.Org/10.3791/3348) In some embodiments, methods for production of AAV libraries comprise one more of the following steps: -Purified and concentrated AAV libraries are diluted in Dulbecco's modified Eagle medium (DMEM) and this is applied to the muscle chamber of a microfluidic device.
-2-10 days after application neuronal cell bodies are harvested either by chemical (i.e. trypsinisation) or mechanical (cell scraping) methods.
-The neurons are lysed and the lysate can either be submitted for deep sequencing (such as RNAseq or DNAseq) to directly detect capsid sequences found in the neurons, or the lysate can be used as a PCR template using primers directed against conserved regions of the AAV capsid. Following PCR of capsid regions the DNA fragment is cloned into a DNA vector and submitted for Sanger sequencing.
-Capsid sequences harvested from neurons are analysed using bioinformatics for conserved regions and highly enriched capsids can be de novo synthesised and can then undergo either further mutagenesis or repeat of in vitro screening to increase evolutionary pressure through directed evolution.
-Directed evolution can be repeated for several rounds (-2-5 rounds). Capsid sequences that show efficient retrograde transport in vitro can be used to generate functional virions for in vivo use In one embodiment the viral particles that selectively infect population-specific neurons (i.e. population-specific AAV viral particles) are used to deliver a nucleotide-encoded payload or exogenous transgene to the population-specific neurons following infection. Advantageously, this payload can be used to deliver gene therapy to targeted cells.
In one embodiment the population-specific AAV viral particles can be used as viral vectors, such as expression vectors. Such expression vectors can be used in gene therapy methods to deliver exogenous transgenes to a subject in need thereof.
Typically, the gene therapy will be used to treat a neurological disorder or condition. One example of a neurological disorder or condition that can be treated by the gene therapy is spasticity. Spasticity is a neurological symptom suffered by people with a variety of neurological disorders, including but not limited to multiple sclerosis, stroke, traumatic brain injury, spinal cord injury, and cerebral palsy. Spasticity results from excessive excitation of muscle by motor neurons, which, because of the disease, become "hyperexcita b le." The invention also comprises methods of treatment which involve injecting AAVs comprising the novel population-specific AAV capsids identified using the screening or directed evolution method disclosed herein into affected muscles of a subject; these AAVs can then infect the distal portion of motor neurons, and are transported to their cell bodies leading to the expression of an exogenous transgene specifically in population-specific neurons innervating that muscle, providing high specificity.
The invention can therefore enable the generation of viral vectors (or expression vectors) that access population-specific neurons and subsequently modify gene expression in the population-specific neurons with the goal of curing, alleviating symptoms, and/or improving the quality of life of patients with diseases affecting, for example, motor neurons.
The invention also comprises methods of treatment which involve injecting AAV viral vectors comprising the novel population-specific AAV capsids into the brain or spinal cord of a subject; these AAV viral vectors can then infect the distal portion of motor neurons, sensory neurons, interneurons or projection neurons of a subject and may selectively infect the distal portions of those neurons in a specific population.
The invention can therefore enable the generation of viral vectors that access these neurons following intracranial, intraspinal or intramuscular injection, and subsequently modify gene expression in these neurons with the goal of curing, alleviating symptoms, and/or improving the quality of life of patients with diseases affecting these neurons.
The capsid nucleotides identified by the present method may be used to develop gene therapies involving viral vectors that access neurons following intramuscular injection, and subsequently modify activity and/or gene expression in neurons. Said nucleotides may also be used to develop gene therapies involving viral vectors that access neurons following intramuscular injection, and subsequently modify activity and/or gene expression in neurons.
In some embodiments, the viral vector is capable of altering the activity of targeted population-specific neurons in a subject. In some embodiments, the viral vector is capable of altering the activity of targeted motor neurons in a subject via intramuscular injection.
In some embodiments, the viral vector further comprises a transgene encoding a transgene product, wherein the transgene product is capable of altering the activity of targeted population-specific neurons in a subject. In some embodiments, the transgene product is capable of altering the activity of targeted population-specific neurons in a subject via intramuscular injection.
In some embodiments methods for the addition of a payload to alter neuron activity may include one or more of the following steps: -Capsid sequences identified in the screening methods described herein are de novo synthesised and inserted into an AAV helper plasmid containing the AAV2 REP gene (Rep/Cap).
-The Rep/Cap plasmid is combined with the AAV backbone and additional plasmids containing adenoviral helper genes (such as pHelper) and transiently transfected into HEK293 cells.
-AAV particles are purified using standard methods and can be used for experiments in vitro or in vivo (e.g. Potter et al., 2014 https://dx.doi.org/10.1038%2Fmtm.2014.34: McClure et al., 2011 http://dx.doi.org/10.3791/3348)-The invention also provides AAV viral particles, for example those produced by the methods described herein.
In some embodiments, the AAVs capsids will be "individualised" to the subject, and the method of treatment will be specific ("personalised") to the subject being treated by generating a personalised organoid.
In some embodiments, the method involves the AAV expression vector or viral particle retrogradely infecting neurons for the purposes of delivering genetic material to neurons, with the purpose of treating neuromuscular or neuromotor disorders, or disorders affecting movement or targeting neurons for any therapeutic purpose.
In some embodiments, the AAV expression vector or viral particle is delivered intramuscularly, in order to infect motor neurons of a subject neuron retrogradely and alter the activity of the motor neurons in a subject.
As used herein, "retrograde transport" or "retrograde infection" means uptake of the vector at the axon terminal (or "synaptic terminal"), i.e., at the synaptic portion, and transport through the axon in a direction opposite to the direction of propagation of action potentials (and thus "retrograde") and into the body of the neuron. Subsequently, the viral nucleic acid can enter the nucleus where it can be replicated and become transcriptionally and translationally active.
Such delivery is advantageous when the neuronal cell body and or axon themselves are inaccessible, but their terminal projection fields including synapses, are available for delivery of the genetic vector. Successful delivery to such a terminal projection field of a genetic vector capable of retrograde transport would thus result in retrograde transport and infection of the vulnerable projection neurons.
Once the viral vector is transported to the body of the neuron, the viral nucleic acid typically localises to the nucleus of the cell. According to some embodiments of the present invention, adeno-associated viral particles that undergo retrograde transport to the neuronal body can insert their nucleic acid content directly into the nucleus.
Embodiments of the invention involve delivery of a substantially non-toxic, recombinant adenoassociated virus vector having a heterologous gene of interest in order to provide retrograde gene delivery to a neuronal cell body resulting in gene expression.
In some embodiments, AAV expression vectors of the invention are capable of treating a neuromuscular or neuromotor disorder by accessing motor neurons following intramuscular injection, and subsequently modifying gene expression in motor neurons, leading to curing, alleviating symptoms, and/or improving the quality of life of patients with diseases affecting motor neurons.
As employed herein, neurological disorder refers to a disorder which causes morphological and/or functional abnormality of a neural cell or a population of neural cells. The neurological disorder can result in an impairment or absence of a normal neurological function or presence of an abnormal neurological function in a subject. For example, neurological disorders can be the result of disease, injury, and/or aging. Non-limiting examples of morphological and functional abnormalities include physical deterioration and/or death of neural cells, abnormal growth patterns of neural cells, abnormalities in the physical connection between neural cells, under-or over production of a substance or substances, e.g., a neurotransmitter, by neural cells, failure of neural cells to produce a substance or substances which it normally produces, production of substances, e.g., neurotransmitters, and/or production or transmission of electrical impulses in abnormal patterns or at abnormal times. As used herein, a "neuromotor disorder" is a developmental or acquired disorder that typically affects movement/gross motor ability, posture, and fine motor ability. The disorder is caused by damage to the central nervous system. This could be due to problems with development or injury to the developing motor pathways in the cortex, basal ganglia, thalamus, cerebellum, brainstem, spinal cord, or peripheral nerve. The most common neuromotor disorders in childhood include cerebral palsy, muscular dystrophy, and spina bifida. The most common neuromotor disorders in adults include stroke, multiple sclerosis, Parkinson's disease and traumatic injury. The impairment may be static (not getting worse) or progressive.
The term "treatment" also includes combination treatments and therapies, in which two or more treatments or therapies are combined, for example, sequentially or simultaneously.
The invention also provides a cell comprising an MV viral vector as described herein. In some embodiments, this cell is a mammalian cell such as a human cell.
In the context of this specification "comprising" is to be interpreted as "including".
Aspects of the invention comprising certain elements are also intended to extend to alternative embodiments "consisting" or "consisting essentially" of the relevant elements.
Where technically appropriate, embodiments of the invention may be combined.
Embodiments are described herein as comprising certain features/elements. The disclosure also extends to separate embodiments consisting or consisting essentially of said features/elements.
Technical references such as patents and applications are incorporated herein by reference.
Any embodiments specifically and explicitly recited herein may form the basis of a disclaimer either alone or in combination with one or more further embodiments.
Examples
Example 1-AAV capsid screening with organoids growing in microfluidic chambers 1. hiPS Cell Culture and Differentiation a. The iPS cells were cultured on a Vitronectin-coated dish with Essential 8 Medium to maintain the undifferentiated state.
b. hiPSCs were dissociated with Accutase, seeded on Matrigel-coated dish with Essential 8 Medium with ROCK inhibitor, and cultured until they reached 80% confluence. hiPSCs were then dissociated with Accutase and resuspended in differentiation medium N2B27 and cultured in non-adherent, ultra-low attachment.
c. At Day 2, Embriod Bodies are formed and were transferred to a new dish and cultured in N2B27 with Chir-99021.
d. At day 4 Retinoic acid and Smoothened Agonist were added.
e. At day 9, DAPT was added.
f. From Day 11 onwards, BDNF and GDNF were added to differentiation media and media was changed every other day.
2. Formation of Motor Nerve Organoids a. The differentiated cells were dissociated by Accutase and seeded in a low-adhesion V-bottom 96-well plate for 10 days to generate spheroids.
b. Microfluidic devices were coated with Matrigel and the spheroids were transferred into one side of the microfluidic chamber. Half of the culture medium was replaced with fresh medium every 4 days.
c. hIPSCs derived myoblasts were plated at the other side of the microfluidic d. Typically, 20-30 days after spheroids are transferred into the microfluidic chamber, an axon fascicle forms within the microgrooves connecting with the muscle cells growing at the other channels.
3. AAV Capsid Libraries addition a. Libraries were added to the side where muscle cells are growing and forming connections with the axonal terminal.
b. Media was changed to the muscle side 8 hours after libraries were added to ensure fluidic isolation between both chamber sides.
4. Collection of Nerve organoids and Capsid sequences rescued by PCR a. After 7 days, Nerve organoids were dissected manually by cutting through the microfluidic device with a razor blade.
b. After collecting spheroids, DNA was extracted from them using a miniprep DNA kit.
c. Capsid sequences that managed to infect the nerve organoids were recovered by PCR using specific capsid primers.
d. The PCR product was cloned back into the library plasmid and packaged into an AAV.
e. Capsid sequences harvested from neurons are analyzed using bioinformatics for conserved regions and highly enriched capsids can be de novo synthesised and can then undergo either further mutagenesis or repeat of in vitro screening to increase evolutionary pressure through directed evolution.
f. Directed evolution can be repeated for several rounds (-2-5 rounds).
Example 2-AAV capsid screening via direct injection of AAV library to organoid compartment 1. hiPS Cell Culture and differentiation a. The hips cells were cultured on a Vitronectin -coated dish with Essential 8 Medium to maintain the undifferentiated state.
b. hips cells were grown for at least three passages and after they reached 70% confluency they were dissociated into single cells using accutase. Single cells were plated on p35 dishes coated with geltrex.
c. The first day the cells were plated in neurobasal medium supplemented with Rock inhibitor, CHIR99021, and bFGF. The next day Rock inhibitor was removed and the cells were maintained in NB medium supplemented with 3uM CHIR99021 and bFGF until day 3. The medium was changed every day.
2. Generation of neuromuscular organoids in 3D a. Neuromesodermal progenitors generated from human PSCs at the previous step were dissociated using accutase to generate a single cell suspension.
b. On day 0 of organoid formation, NMP cells were plated on an ultra-low binding 96-well plate in Neurobasal medium with Rho-associated protein kinase ROCK inhibitor, bFGF and IGF1 and HGF.
c. After day 4 the organoids were maintained in NB medium without the addition of growth factors.
d. On day 10 the organoids were transferred in 60mm dishes in 5 mL of medium and after 1 month in 100mm dishes with 12 mL NB medium. During the whole period organoids were maintained on an orbital shaker rotating at 75 rpm.
3. AAV Capsid Libraries addition a. AAV libraries were microinjected at the muscle side of the neuromuscular organoid.
b. Organoids were maintained on an orbital shaker for 7 days.
2. Collection of Nerve organoids and Capsid sequences rescued by PCR a. After 7 days, Nerve organoids were micro dissected manually by cutting through the organoid with a micro scalpel.
b. After collecting the neuronal side, DNA was extracted from them using a miniprep DNA kit.
c. Capsid sequences that managed to infect the nerve organoids were recovered by PCR using specific capsid primers.
d. The PCR product was cloned back into the library plasmid and packaged into an AAV.
e. Capsid sequences harvested from neurons are analyzed using bioinformatics for conserved regions and highly enriched capsids can be de novo synthesised and can then undergo either further mutagenesis or repeat of in vitro screening to increase evolutionary pressure through directed evolution.
f. Directed evolution can be repeated for several rounds (-2-5 rounds).
Claims (11)
- Claims 1. A method of screening for capsid-encoding nucleotide sequences of AAV viral particles capable of infecting population-specific neurons, the method comprising: (i) obtaining or having obtained a neuromuscular organoid comprising neurons and muscle cells, wherein the neurons, having a cell body and a distal portion located away from the cell body, are disposed in the organoid such that the cell body and the distal portion are distally separated from each other; (ii) contacting the distal portion of the neurons with a population of AAV viral particles such that they can infect the neuron at the distal portion; (iii) recovering AAV viral particles that have infected the distal portion of the neurons from the cell body; and (iv) determining the capsid encoding nucleotide sequences of the AAV viral particles recovered from the cell body.
- 2. A method of directed evolution to select for AAV viral particles capable of selectively infecting population-specific neurons comprising the steps: (i) obtaining or having obtained a neuromuscular organoid comprising neurons and muscle cells, wherein the neurons, having a cell body and a distal portion located away from the cell body, are disposed in the organoid such that the cell body and the distal portion are distally separated from each other; (ii) contacting the distal portion of the neurons with a population of AAV viral particles such that they can infect the neuron at the distal portion; (iii) recovering AAV viral particles that have infected the distal portion of the neurons from the cell body; (iv) determining the capsid encoding nucleotide sequences of the AAV viral particles recovered from the cell body, and (v) optionally using the output of step (iv) to generate a new AAV viral particle library and repeating the method.
- 3. The method according to any preceding claim wherein the neuromuscular organoid is derived from iPSCs or ESCs.
- 4 The method according to any preceding claim wherein the population-specific neurons are selected from the list consisting: mammalian, human, human sub-population and human disease-specific.
- 5. The method according to claim 4 wherein the human disease-specific population-specific neurons are selected from the list: MND, DM, ALS, HD, epilepsy, neuropathy, PD, SCA, HSP, PLS, SMA, SBMA and LCCS neurons.
- 6. AAV viral particles capable of infecting population-specific neurons identified or selectively evolved according to the method of any preceding claim.
- 7. Use of the AAV viral particles according to claim 6 to selectively infect population-specific neurons.
- 8. The use according to claim 7 wherein the AAV viral particle comprises a nucleotide-encoded payload.
- 9 The use according to claim 8 wherein the nucleotide-encoded payload encodes a therapeutic peptide.
- 10. The use according to claim 8 or claim 9 wherein the nucleotide-encoded payload is a gene therapy payload.
- 11. Use of the AAV viral particles according to claim 6 in the treatment of a disease caused by a genetic mutation.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2213924.0A GB2622629A (en) | 2022-09-23 | 2022-09-23 | Method |
PCT/IB2023/059404 WO2024062450A1 (en) | 2022-09-23 | 2023-09-22 | Method of screening aav viral particle libraries in organoids |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2213924.0A GB2622629A (en) | 2022-09-23 | 2022-09-23 | Method |
Publications (2)
Publication Number | Publication Date |
---|---|
GB202213924D0 GB202213924D0 (en) | 2022-11-09 |
GB2622629A true GB2622629A (en) | 2024-03-27 |
Family
ID=83978750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB2213924.0A Pending GB2622629A (en) | 2022-09-23 | 2022-09-23 | Method |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB2622629A (en) |
WO (1) | WO2024062450A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022008757A1 (en) * | 2020-07-10 | 2022-01-13 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | A method for generating a three-dimensional neuromuscular organoid in vitro |
WO2022013396A1 (en) * | 2020-07-16 | 2022-01-20 | Ucl Business Ltd | Gene therapy for neuromuscular and neuromotor disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8632764B2 (en) | 2008-04-30 | 2014-01-21 | University Of North Carolina At Chapel Hill | Directed evolution and in vivo panning of virus vectors |
EP2826860B1 (en) | 2010-04-23 | 2018-08-22 | University of Massachusetts | CNS targeting AAV vectors and methods of use thereof |
ES2739288T3 (en) | 2013-09-13 | 2020-01-30 | California Inst Of Techn | Selective recovery |
KR102423442B1 (en) | 2015-12-11 | 2022-07-20 | 캘리포니아 인스티튜트 오브 테크놀로지 | Targeting Peptides for Directing Adeno-Associated Viruses |
-
2022
- 2022-09-23 GB GB2213924.0A patent/GB2622629A/en active Pending
-
2023
- 2023-09-22 WO PCT/IB2023/059404 patent/WO2024062450A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022008757A1 (en) * | 2020-07-10 | 2022-01-13 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | A method for generating a three-dimensional neuromuscular organoid in vitro |
WO2022013396A1 (en) * | 2020-07-16 | 2022-01-20 | Ucl Business Ltd | Gene therapy for neuromuscular and neuromotor disorders |
Non-Patent Citations (1)
Title |
---|
Molecular Therapy, vol. 19, no. 4, 2011, Jae-Hyung Jang et al., "An Evolved Adeno-associated Viral Variant Enhances Gene Delivery and Gene Targeting in Neural Stem Cells", p. 667-675. * |
Also Published As
Publication number | Publication date |
---|---|
WO2024062450A1 (en) | 2024-03-28 |
GB202213924D0 (en) | 2022-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bedbrook et al. | Viral strategies for targeting the central and peripheral nervous systems | |
US10287607B2 (en) | Tissue selective transgene expression | |
CN109641939B (en) | Variant adeno-associated viruses and methods of use | |
El-Shamayleh et al. | Strategies for targeting primate neural circuits with viral vectors | |
WO2014143932A1 (en) | Synthetic adeno-associated virus inverted terminal repeats | |
JP2022513426A (en) | Artificial expression constructs for selectively regulating gene expression in cortical excitatory neurons | |
Flytzanis et al. | Broad gene expression throughout the mouse and marmoset brain after intravenous delivery of engineered AAV capsids | |
Sun et al. | Engineered viral vectors for functional interrogation, deconvolution, and manipulation of neural circuits | |
TW202128736A (en) | Adeno-associated viral vectors for treatment of niemann-pick disease type c | |
JP2022533448A (en) | UBE3A genes and expression cassettes and their uses | |
Hutson et al. | Trans-neuronal transduction of spinal neurons following cortical injection and anterograde axonal transport of a bicistronic AAV1 vector | |
GB2622629A (en) | Method | |
Hirai | Progress in transduction of cerebellar Purkinje cells in vivo using viral vectors | |
US20230332178A1 (en) | Gene therapy for neuromuscular and neuromotor disorders | |
US20220098254A1 (en) | NEUROD1 and DLX2 VECTOR | |
US20220106614A1 (en) | Dlx2 vector | |
US20220106613A1 (en) | Neurod1 vector | |
Day | Expanding the potential of adeno-associated virus for the treatment of intractable inherited retinal degenerations | |
Chen | Data-Driven Design and Prediction of Adeno-Associated Virus Tropisms | |
WO2023150553A1 (en) | Gpr17 promoter-based targeting and transduction of glial progenitor cells | |
WO2023164448A1 (en) | Chimeric neurotropic aav capsids | |
Lin et al. | Identification of Cis-Regulatory Modules for Aav-Based Cell Type-Specific Targeting in the Retina and Brain | |
EA044679B1 (en) | VARIANT ADEN-ASSOCIATED VIRUSES AND METHODS OF THEIR APPLICATION |